Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Sep 23;230(3):e647-e656.
doi: 10.1093/infdis/jiae081.

Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults

Christine A Shaw  1 , Brandon Essink  2 , Charles Harper  2 , Runa Mithani  1 , Archana Kapoor  1 , Rakesh Dhar  1 , Lauren Wilson  1 , Ruiting Guo  1 , Catherine A Panozzo  1 , Eleanor Wilson  1 , Alana K Simorellis  1 , Caroline Reuter  1 , Sonia K Stoszek  1 , Grace L Chen  1 , Rituparna Das  1 , Jaya Goswami  1
Affiliations
Clinical Trial

Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults

Christine A Shaw et al. J Infect Dis. .

Abstract

Background: An mRNA-based respiratory syncytial virus (RSV) vaccine, mRNA-1345, is under clinical investigation to address RSV disease burden in older adults.

Methods: Based on a randomized, observer-blind, placebo-controlled design, this phase 1 dose-ranging study evaluated the safety, reactogenicity, and immunogenicity of mRNA-1345 in adults aged 65 to 79 years. Participants were randomized to receive 1 dose of mRNA-1345 (12.5, 25, 50, 100, or 200 µg) or placebo and matched mRNA-1345 booster or placebo at 12 months.

Results: Overall, 298 participants received the first injection and 247 received the 12-month booster injection. mRNA-1345 was generally well tolerated after both injections, with the most frequently reported solicited adverse reactions being injection site pain, fatigue, headache, arthralgia, and myalgia. Reactogenicity was higher after the booster injection but with severity, time to onset, and duration similar to the first injection. A single mRNA-1345 injection boosted RSV-A and RSV-B neutralizing antibody titers and prefusion F binding antibody (preF bAb) concentrations at 1 month (geometric mean fold rises: RSV-A, 10.2-16.5; RSV-B, 5.3-12.5; preF bAb, 7.2-12.1). RSV antibody levels remained above baseline through 12 months, indicating immune persistence. A 12-month booster injection also increased RSV-A and RSV-B neutralizing antibody titers and preF bAb concentrations; titers after booster injection were numerically lower than those after the first dose, with overlapping 95% CIs.

Conclusions: mRNA-1345 was well tolerated and immunogenic following a single injection and a 12-month booster.

Clinical trials registration: NCT04528719 (ClinicalTrials.gov).

Keywords: mRNA vaccine; mRNA-1345; older adult; respiratory syncytial virus; safety and immunogenicity.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. C. A. S., R. M., A. K., R. D., L. W., C. A. P., J. G., E. W., R. G., A. K. S., C. R., S. K. S., and G. L. C. are employees of Moderna, Inc, and may hold stock/stock options in the company. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
Schematic diagram of the planned treatment groups.
Figure 2.
Figure 2.
Solicited local and systemic adverse reactions within 7 days of receiving the first and booster injections. Number of participants per group after the first injection: placebo, n = 58; mRNA-1345, 12.5 µg, n = 46; 25 µg, n = 48; 50 µg, n = 47; 100 µg, n = 48; 200 µg, n = 47. Number of participants per group after booster injection: placebo/placebo, n = 51; mRNA-1345, 12.5 µg/placebo, n = 19; 12.5 µg/12.5 µg, n = 21; 25 µg/placebo, n = 20; 25 µg/25 µg, n = 22; 50 µg/placebo, n = 21; 50 µg/50 µg, n = 18; 100 µg/placebo, n = 18; 100 µg/100 µg, n = 18; 200 µg/placebo, n = 16; 200 µg/200 µg, n = 20.
Figure 3.
Figure 3.
A, RSV-A and RSV-B neutralizing antibody GMTs and GMFR. B, preF and postF binding GMCs by time after the first injection (per-protocol set). GMC, geometric mean concentration; GMFR, geometric mean fold rise; GMT, geometric mean titer; postF, post–fusion F; preF, pre–fusion F; RSV, respiratory syncytial virus.
Figure 4.
Figure 4.
Serum RSV-A (A) and RSV-B (B) neutralizing antibody kinetics at baseline following the first injection and booster injection (per-protocol booster subset). GMT, geometric mean titer; RSV, respiratory syncytial virus.
See this image and copyright information in PMC

References

    1. Li Y, Reeves RM, Wang X, et al. Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis. Lancet Glob Health 2019; 7:e1031–45. - PubMed
    1. Centers for Disease Control and Prevention . Respiratory syncytial virus (RSV) symptoms and care. Available at: https://www.cdc.gov/rsv/about/symptoms.html#:∼:text=Take%20steps%20to%20.... Accessed 30 March 2022.
    1. Shi T, Denouel A, Tietjen AK, et al. Global disease burden estimates of respiratory syncytial virus–associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis. J Infect Dis 2020; 222:S577–83. - PubMed
    1. Centers for Disease Control and Prevention . RSV in older adults and adults with chronic medical conditions. Available at: https://www.cdc.gov/rsv/high-risk/older-adults.html#:∼:text=Older%20adul.... Accessed 5 April 2022.
    1. Centers for Disease Control and Prevention . RSV in infants and young children. Available at: https://www.cdc.gov/rsv/high-risk/infants-young-children.html. Accessed 4 April 2023.

Publication types

MeSH terms

Associated data

Grants and funding